Navigation Links
Labtec’s Next Generation Pain Patch Successful in Clinical,Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld, Germany), a specialty pharmaceutics company announces positive results from a multiple dose clinical study for their proprietary Sufentanil transdermal patch.

“Today, we are pleased to announce the successful completion of the second clinical trial for our Sufentanil TDS®. Our goal for this program was to complete this study in the first half of 2007,” says Dr. Armin Breitenbach, Labtec's Director of Pharmaceutical Development. “Based on the positive results of the first Phase I trial for our Sufentanil patch that showed good safety, tolerability and extended drug release, we initiated this trial end of last year. The objectives to demonstrate effective plasma levels and safety of repetitive applications of our Sufentanil patch were fully met. We believe that this product, once approved, will provide a significant improvement over currently available pain management therapies on the market today.”

Labtec's transdermal Sufentanil product is intended to provide extended chronic pain relief for several days. The patch is not only very small but at the same time has an unusually low drug content. The proprietary formulation releases the drug with an unparalleled efficiency. Additional patient comfort is achieved by the use of a special non-woven backing. Unlike most backing films used in transdermal systems, this material is non-occlusive, allows the skin to breathe and maintains its integrity throughout the application period.

“After the huge success story of our Fentanyl patch, which is marketed by our licensee ratiopharm and several other leading generic companies in Europe, we are looking forward to see our Sufentanil TDS® move forward. In our opinion this transdermal patch is the logical next generation product for severe chronic pain. Sufentanil is one of the most potent drugs in its class,
'"/>




Page: 1 2

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
4. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
5. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
6. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
10. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Labtec Next Generation Pain Patch Successful Clinical Studies
(Date:8/27/2014)... 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... following financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over ... loss for the quarter of $240,156 compared to net income ... For the nine months ended June 30, ...
(Date:8/27/2014)... Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... H. Mackaness is scheduled to make an investor presentation ... 2:55 p.m. Eastern Time on Wednesday, September 3, in New ... the investor presentation will be available in the Investors section ... About IRIDEX IRIDEX Corporation was founded in ...
(Date:8/27/2014)... CITY, Calif. , Aug. 27, 2014  AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today announced that senior management will be participating ... presenting at the Morgan Stanley Global Healthcare Conference.  Details ... FBR Healthcare One on One Conference Date: Wednesday September ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Maleic Anhydride ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... IQ Formulations , a leading manufacturer of ... of the Cystic Fibrosis Foundation. For an entire month ... led by TigerFitness.com in which 5 percent of the ... to the respected nonprofit organization. , Last year, ... Isla, a young girl fighting Cystic Fibrosis. The company ...
(Date:8/27/2014)... 27, 2014 Aspirus Wausau Hospital today ... US with Buzz™ Digital O.R. at Aspirus Wausau Hospital, ... 13 new operating rooms will be Buzz, a centralized ... integrative system supports planning, navigation, imaging and communications connectivity. ... of intuitive software and hardware all controlled from the ...
(Date:8/27/2014)... August 27, 2014 SCOTT Sports ... Park, Utah’s first indoor mountain bike and BMX park. ... park-style bikes in both adult and youth sizes for the ... operated a distribution warehouse in Ogden, Utah, recently moved its ... , “We are proud to be a partner with the ...
(Date:8/27/2014)... Steven Reinberg HealthDay Reporter ... hormone used to reduce the need for blood transfusions might ... suggests. Synthetic erythropoietin (EPO), which stimulates red blood cell ... preterm birth, said lead researcher Dr. Petra Huppi, a professor ... in Switzerland. "The real test of whether EPO protects ...
Breaking Medicine News(10 mins):Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3
... WASHINGTON, DCThrough the identification of a gene,s impact on ... Center continue to make progress in understanding the ... repair of white matter, known as myelination. The study, ... of The Journal of Neuroscience , identified ...
... of the 5.3 million men and women seen in Department ... that use of cocaine is predictive of open-angle glaucoma, the ... that after adjustments for race and age, current and former ... Men with open-angle glaucoma also had significant exposures to amphetamines ...
... found that patients had little or no control over their ... care, but a new study shows that this has changed ... with health coverage that includes a high deductible and either ... their costs even after they initiated care. ...
... THURSDAY, Sept. 29 (HealthDay News) -- The bellowing of male ... researchers report. They found that the largest koalas produce ... males that they,re the biggest dudes in the neighborhood. ... few animals with a descended larynx, which makes the vocal ...
... their everyday lives and with support from partners can continue ... of the preliminary findings of a two-year research project funded ... married couples living with dementia make decisions on a daily ... over issues such as what to eat or wear, as ...
... , WEDNESDAY, Sept. 28 (HealthDay News) -- Cancer patients ... can have serious side effects and even mean the ... crucial that patients insist doctors use plain language ... associate professor of internal medicine at the University of ...
Cached Medicine News:Health News:Children's National researchers make breakthrough in understanding white matter development 2Health News:Children's National researchers make breakthrough in understanding white matter development 3Health News:Cocaine users have 45 percent increased risk of glaucoma 2Health News:Study finds consumers may have more control over health costs than previously thought 2Health News:Study finds consumers may have more control over health costs than previously thought 3Health News:Living with dementia and making decisions 2Health News:Cancer Patients Should Ask Doctors to Use Simple Terms 2
Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
The humidity chamber maintains a moist environment during immunostaining procedures as well as other laboratory procedures requiring controlled incubation steps....
Thermostatically controlled, large capacity surface to quickly evaporate water and solvents from slides and mounting media....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: